News | September 13, 2021
Zydus Cadila seeks approval for a two-dose ZyCoV-D Covid-19 vaccine
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
Lenalidomide is used to treat cancer and also some anaemia disorders
The group has a total of 320 ANDA approvals
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The group now has 320 approvals and has so far filed over 400 ANDAs
The company had announced the expected date of completion of sale and disposal of the said undertaking is 90 days from the date of signing the Definitive Agreements.
The drug is used with other HIV medications to help control HIV infection and it helps to decrease the amount of HIV in one’s body so that the immune system can work better
Subscribe To Our Newsletter & Stay Updated
